Intuitive Surgical's Financial Outlook Ahead of Earnings Release
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy ISRG?
Source: NASDAQ.COM
- Stock Performance: Intuitive Surgical, Inc. closed at $472.16, reflecting a 1.48% decline from the previous day, yet it has gained 0.14% over the past month, outperforming the Medical sector's 4.48% loss, indicating relative resilience.
- Financial Expectations: The upcoming earnings report is projected to show an EPS of $2.08, a 14.92% increase year-over-year, with revenue expected at $2.61 billion, up 15.86% from the prior year, highlighting the company's strong market performance and profit potential.
- Analyst Confidence: The Zacks Consensus Estimates suggest analysts expect full-year earnings of $10.06 per share and revenue of $11.56 billion, representing increases of 12.65% and 14.86% respectively from last year, reflecting confidence in the company's future performance.
- Valuation Analysis: Intuitive Surgical currently trades at a forward P/E ratio of 47.62, significantly above the industry average of 20.03, while its PEG ratio stands at 3.03, indicating market expectations for future growth, with the company ranked in the top 37% of the Medical Instruments industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 451.380
Low
575.00
Averages
637.32
High
740.00
Current: 451.380
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
Intuitive Surgical's Growth Driven by da Vinci Robots and Services
- Significant Sales Growth: Intuitive Surgical installed 431 da Vinci surgical systems in Q1 2026, up 17% from 367 a year earlier, indicating robust market demand and reinforcing its leadership in the surgical robotics sector.
- Diverse Revenue Sources: While da Vinci robot sales are strong, they account for only 23% of total revenue, with instruments and accessories making up a substantial 60%, highlighting the company's ongoing profitability from post-surgical services and product sales.
- Surgery Volume Increase: The number of surgeries performed with da Vinci robots rose 17% year-over-year in Q1 2026, significantly outpacing the 12% increase in robot installations, demonstrating strong demand that further drives accessory and service sales.
- Long-Term Revenue Potential: Intuitive Surgical's parts and services revenue has annuity-like characteristics, as the sale of additional accessories and services will continue to grow with each new da Vinci robot sold, creating a sustainable revenue growth model.
See More
Intuitive Surgical's Growth Beyond Robot Sales
- Strong Market Demand: In Q1 2026, Intuitive Surgical installed 431 da Vinci systems, a 17% increase from 367 a year earlier, indicating robust demand for surgical robots that drives ongoing company growth.
- Revenue Structure Analysis: Despite strong sales of da Vinci robots, they account for only 23% of total revenue, while 60% comes from instruments and services, highlighting the company's ongoing profitability in post-surgical support.
- Surgery Volume Growth: The number of surgeries performed with da Vinci robots increased by 17% year-over-year in Q1 2026, significantly outpacing the 12% growth in robot numbers, demonstrating strong surgical demand that further boosts sales of parts and services.
- Long-Term Profitability Model: Intuitive Surgical's parts and services revenue is annuity-like, meaning as more da Vinci systems are sold, the ongoing demand for parts and services will continue to grow, creating a powerful profit driver.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Healthcare Giants Face Challenges and Opportunities Ahead
- Underperformance: Both Intuitive Surgical and Vertex Pharmaceuticals have significantly underperformed the market this year, facing challenges such as tariffs on medical devices and setbacks in drug diversification, which have shaken investor confidence in their growth prospects.
- Increased Competition: Intuitive Surgical is facing heightened competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; while its financial performance remains strong, the pressure on market share could impact its long-term profitability.
- Valuation Concerns: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare industry's average of 16.5, and although its long-term investment value is still viewed positively, the high valuation may cause short-term investors to feel uneasy.
- Future Growth Potential: Vertex Pharmaceuticals' cystic fibrosis drug business is expected to continue generating revenue until the mid-2030s, and its plans for new drug development and market expansion could drive future revenue growth, despite a current stock price decline of 14%.
See More
Healthcare Giants Face Challenges and Opportunities
- Increased Competition: Intuitive Surgical faces heightened competition from Medtronic's Hugo system, which has received clearance for urologic procedures, potentially impacting its market share in robotic-assisted surgery, especially if competition intensifies and revenue growth slows.
- Strong Financial Performance: Despite tariff and competitive pressures, Intuitive Surgical reported significant revenue and earnings growth in Q1, with expanded gross margins, indicating strong potential in the robotic surgery market, making it attractive for long-term investors.
- Mature Drug Market: Vertex Pharmaceuticals' core therapeutic area is performing well, but as it matures, the growth driver has weakened, leading to a 14% decline in stock price over the past year, necessitating new drug development to stimulate sales growth.
- Promising Drug Development: Vertex is developing new therapies like povetacicept for IgA nephropathy, with positive early-stage results suggesting potential approval, which could provide new growth drivers and enhance its competitive position in the market.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
Intuitive Surgical's Growth Driven by da Vinci Robots and Services
- Significant Sales Growth: Intuitive Surgical installed 431 da Vinci surgical systems in Q1 2026, up 17% from 367 a year earlier, indicating robust market demand and reinforcing its leadership in the surgical robotics sector.
- Diverse Revenue Sources: While da Vinci robot sales are strong, they account for only 23% of total revenue, with instruments and accessories making up a substantial 60%, highlighting the company's ongoing profitability from post-surgical services and product sales.
- Surgery Volume Increase: The number of surgeries performed with da Vinci robots rose 17% year-over-year in Q1 2026, significantly outpacing the 12% increase in robot installations, demonstrating strong demand that further drives accessory and service sales.
- Long-Term Revenue Potential: Intuitive Surgical's parts and services revenue has annuity-like characteristics, as the sale of additional accessories and services will continue to grow with each new da Vinci robot sold, creating a sustainable revenue growth model.
See More
Intuitive Surgical's Growth Beyond Robot Sales
- Strong Market Demand: In Q1 2026, Intuitive Surgical installed 431 da Vinci systems, a 17% increase from 367 a year earlier, indicating robust demand for surgical robots that drives ongoing company growth.
- Revenue Structure Analysis: Despite strong sales of da Vinci robots, they account for only 23% of total revenue, while 60% comes from instruments and services, highlighting the company's ongoing profitability in post-surgical support.
- Surgery Volume Growth: The number of surgeries performed with da Vinci robots increased by 17% year-over-year in Q1 2026, significantly outpacing the 12% growth in robot numbers, demonstrating strong surgical demand that further boosts sales of parts and services.
- Long-Term Profitability Model: Intuitive Surgical's parts and services revenue is annuity-like, meaning as more da Vinci systems are sold, the ongoing demand for parts and services will continue to grow, creating a powerful profit driver.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Healthcare Giants Face Challenges and Opportunities Ahead
- Underperformance: Both Intuitive Surgical and Vertex Pharmaceuticals have significantly underperformed the market this year, facing challenges such as tariffs on medical devices and setbacks in drug diversification, which have shaken investor confidence in their growth prospects.
- Increased Competition: Intuitive Surgical is facing heightened competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; while its financial performance remains strong, the pressure on market share could impact its long-term profitability.
- Valuation Concerns: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare industry's average of 16.5, and although its long-term investment value is still viewed positively, the high valuation may cause short-term investors to feel uneasy.
- Future Growth Potential: Vertex Pharmaceuticals' cystic fibrosis drug business is expected to continue generating revenue until the mid-2030s, and its plans for new drug development and market expansion could drive future revenue growth, despite a current stock price decline of 14%.
See More
Healthcare Giants Face Challenges and Opportunities
- Increased Competition: Intuitive Surgical faces heightened competition from Medtronic's Hugo system, which has received clearance for urologic procedures, potentially impacting its market share in robotic-assisted surgery, especially if competition intensifies and revenue growth slows.
- Strong Financial Performance: Despite tariff and competitive pressures, Intuitive Surgical reported significant revenue and earnings growth in Q1, with expanded gross margins, indicating strong potential in the robotic surgery market, making it attractive for long-term investors.
- Mature Drug Market: Vertex Pharmaceuticals' core therapeutic area is performing well, but as it matures, the growth driver has weakened, leading to a 14% decline in stock price over the past year, necessitating new drug development to stimulate sales growth.
- Promising Drug Development: Vertex is developing new therapies like povetacicept for IgA nephropathy, with positive early-stage results suggesting potential approval, which could provide new growth drivers and enhance its competitive position in the market.
See More
